IDL Biotech förbereder kliniska studier i USA för sitt snabbtest för blåscancer, UBC® Rapid

Under 2019 lämnade IDL Biotech in underlag, en så kallad ”pre-submission request”, till amerikanska FDA (Food and Drug Administration) för att kunna få ett framtida godkännande av UBC® Rapid, bolagets snabbtest för blåscancer. Nu går bolaget vidare och förbereder kliniska studier i USA.

Read the article

Christmas Holiday

We would like to inform you that our office will be closed, due to Christmas and New Years Holidays during the following period December 22nd 2019 to January 5th, 2020. Full operations will resume on January the 6th.

Read the article

Meet us

IDL will attend the following meetings during autumn 2018

Read the article

Patent approved in Europe

During 2015 the patent ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034.

Read the article

Articles

Latest News

May 2019

Information from the Annual General Meeting

IDL Biotech förbereder kliniska studier i USA för sitt snabbtest för blåscancer, UBC® Rapid

Christmas Holiday

Meet us

Patent approved in Europe